Dr. Cedrik M. Britten is the head of Cell Therapy in the Immuno-Oncology and Combinations Unit at GlaxoSmithKline. Dr. Britten is renowned for his work on biomarkers, and his development of frameworks for personalized medicine approaches and technology commercialization. At GSK, his group’s focus is on developing novel immunotherapies involving engineered immune cells. Dr. Britten is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.
Developing new treatments to address the huge unmet medical need in oncology is a global challenge. Fortunately, we have reached a deeper understanding of immune therapies, and we now have the tools to make the next leap forward toward more effective immunotherapies and their broader use.
Let's spread the word about Immunotherapy! Click to share this page with your community.